Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed: De novo design model

34Citations
Citations of this article
69Readers
Mendeley users who have this article in their library.

Abstract

The SARS-CoV-2 main viral protease (Mpro) is an attractive target for antivirals given its distinctiveness from host proteases, essentiality in the viral life cycle and conservation across coronaviridae. We launched the COVID Moonshot initiative to rapidly develop patent-free antivirals with open science and open data. Here we report the use of machine learning for de novo design, coupled with synthesis route prediction, in our campaign. We discover novel chemical scaffolds active in biochemical and live virus assays, synthesized with model generated routes. This journal is

Cite

CITATION STYLE

APA

Morris, A., McCorkindale, W., Drayman, N., Chodera, J. D., Tay, S., London, N., & Lee, A. A. (2021). Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed: De novo design model. Chemical Communications, 57(48), 5909–5912. https://doi.org/10.1039/d1cc00050k

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free